Business
Atara develops T-cell immunotherapies around an allogeneic Epstein-Barr virus platform, with tab-cel approved as Ebvallo in Europe, the UK, and Switzerland through a partner.
Atara moved to reported profitability in FY2025, but revenue fell, free cash flow stayed negative, equity stayed negative, and forensic screens were stressed.
The read at a glance✓ Audited against SEC data
- Business mix — T-cell immunotherapy platformNote
- Revenue — Revenue fell 6.3%Watch
- Profit — Net income was $32.7MOK
- Cash — FCF was -$50.9MWatch
- Balance sheet — Equity remained negativeWatch
- Insiders — 2 buys / 7 sellsNote
- Accounting — Altman-Z distress; Beneish flag; EQ greyWatch
Leadership changes
From Atara Biotherapeutics, Inc.'s own filings, the day they're filed.
- Kevin G. Sarney · chief financial officer · appointmenteff. 2026-07-17
- Brian Cherry · director · appointmenteff. 2026-06-11
- Ameet Mallik · departureeff. 2025-09-02
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-06-26
- 8-K · Company announcement2026-06-12
- 10-Q · Quarterly report2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Atara Biotherapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.